Revenue
No reported data
Transcode Therapeutics, Inc. (RNAZ)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $13.4M | $9.7M | $12.3M | $10.2M | $2.8M | $284,459 |
| Operating expenses | $28.0M | $15.7M | $19.4M | $18.6M | $6.2M | $726,604 |
| Operating income | −$28.0M | −$15.7M | −$19.4M | −$18.6M | −$6.2M | −$726,604 |
| EBITDAderived | −$27.9M | −$15.6M | −$19.3M | −$18.5M | −$6.1M | −$726,604 |
| Net income | −$34.7M | −$16.8M | −$18.5M | −$17.6M | −$6.8M | −$2.3M |
| Basic EPSper diluted share | -$52.59 | -$1,336.63 | -$3,419.01 | -$1,082.79 | -$0.81 | -$0.51 |
| Diluted EPSper diluted share | -$52.59 | -$1,336.63 | -$3,419.01 | -$1,082.79 | -$0.81 | -$0.51 |